Study of EYP-1901 in Patients With Diabetic Macular Edema (DME) - Trial NCT06099184
Access comprehensive clinical trial information for NCT06099184 through Pure Global AI's free database. This Phase 2 trial is sponsored by EyePoint Pharmaceuticals, Inc. and is currently Not yet recruiting. The study focuses on Diabetic Macular Edema. Target enrollment is 25 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
EyePoint Pharmaceuticals, Inc.
Timeline & Enrollment
Phase 2
Jan 15, 2024
Jan 15, 2025
Primary Outcome
Time to first supplemental aflibercept injection following EYP-1901 dose at Baseline vs Aflibercept
Summary
A prospective, randomized, single-masked study evaluating the ocular efficacy and safety of
 two doses of the EYP-1901 intravitreal insert compared to aflibercept
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06099184
Non-Device Trial